Navigation Links
Alimera Sciences Reports First Quarter 2013 Financial Results
Date:5/9/2013

ough the National Health Service. The NICE Appraisal Committee is scheduled to meet on May 15, 2013 to discuss the ILUVIEN PAS and will communicate its decision at a later date.

FDA UpdateAlimera recently announced that its resubmission of the New Drug Application (NDA) for ILUVIEN has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's November 2011 letter and that a new Prescription Drug User Fee Act (PDUFA) goal date of October 17, 2013 has been established. In the resubmission, Alimera responded to questions raised in the FDA's letter and provided additional analyses as well as new information to support that ILUVIEN is safe and effective in the treatment of patients with chronic DME. The resubmission focused on the safety aspects of ILUVIEN and the subgroup population of patients with chronic DME, the same subgroup for which marketing approval for ILUVIEN has been granted in six countries in the European Union. Alimera used existing data from two previously completed pivotal Phase 3 clinical trials (collectively called the FAME™ Study).

"We are pleased to have recently learned of the PDUFA goal date for our NDA for ILUVIEN in the fall and look forward to the FDA's response," said Mr. Myers.

First Quarter 2013 Financial Results Research and development expenses for the first quarter of 2013 increased to $2.0 million, compared to $1.6 million for the first quarter of 2012. The increase was primarily attributable to preparation of the resubmission of the NDA for ILUVIEN. In the event the FDA approves Alimera's NDA for ILUVIEN, Alimera will owe an additional milestone payment of $25.0 million to pSivida Corp.

General and administrative expenses in the first quarter of 2013 were $2.7 million, compared to $1.4 million in the first quarter of 2012. The increase was primarily due to infrastructure build and financial and operational planning for Alimera's
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alimera Sciences Secures $20 Million Debt Facility
2. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
3. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
4. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
5. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
6. Alimera Sciences Names European Management Team
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
9. Sangamo BioSciences Reports First Quarter 2013 Financial Results
10. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
11. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % ... , India Business grew by 20.87% to Rs. 3,971.59 ... Mn Rest of World (ROW) Business grew by 20.67% ... 34.53% to Rs. 977.26 Mn Latin America Business grew ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
(Date:7/24/2014)... 2014 Cancer patients in the west of ... treatment closer to home when a new radiotherapy center opens ... Systems (NYSE: VAR ) has been selected to ... June for four TrueBeam™ medical linear accelerators. ... efficient radiotherapy and radiosurgery treatments, will replace older treatment machines ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Mass., Dec. 8, 2010 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that although ... of care for first- and second-line treatment of ... replace paclitaxel/carboplatin as the standard second-line treatment for ...
... 8, 2010 Sunridge International (OTC Bulletin Board: ... preparing to start the short term clinical trials needed ... L.L.C., Sunridge,s exclusive distributor for several Middle Eastern countries, ... to attend the start of their clinical trials.  Dr. ...
Cached Medicine Technology:For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 2For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 3
(Date:7/24/2014)... PHILADELPHIA For rats bearing human breast tumors, exposure ... to the breast cancer drug tamoxifen, according to data ... the American Association for Cancer Research. The negative effects ... by giving rats a melatonin supplement during the night. ... patients with hormone receptor-positive breast cancer," said Steven M. ...
(Date:7/24/2014)... Denver, CO (PRWEB) July 24, 2014 Ticket ... vs. AS Roma Tickets in Denver at the Sports Authority ... Champions Cup (or World Football Challenge) has brought some of the ... a mini-tournament. With the World Cup still being raved about weeks ... have the chance to see some of the biggest stars in ...
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuits ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. ... qualified protective order for plaintiff medical information covered ... Act. According to the July 16th Order, U.S. ... attorneys for Fresenius Medical Care the right ...
(Date:7/24/2014)... (ASAE) announced its 2014 Power of A Award winners, ... Anesthesiologists (ASA). , The ASA Global Humanitarian Outreach ... one of the top honors from ASAE. GHO was ... through education on the global anesthesia crisis and supporting ... was also honored with a Power of A Silver ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... Oct. 9 Actor Joe Pantoliano,reveals a personal ... mother,struggled with untreated bipolar disorder, in a guest ... National Alliance on Mental,Illness (NAMI)., Pantoliano,s entry ... a few days before the opening of his ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... heart attack risk, study finds , , TUESDAY, Oct. 9 (HealthDay ... who has had a heart attack will have another major ... shown that workplace stress boosts heart woes, but this is ... and other major events, the report,s authors said. , The ...
... Johns Hopkins scientists have developed a potentially novel way ... potent barrages of radiation inside cancer cells, unlike current ... attack from the outside and cause unwanted side effects. ... cells, the new radiation delivery system proved able to ...
... The March of,Dimes congratulates Mario R. Capecchi, Ph.D., ... D.Phil., FRS, former recipients of the,March of Dimes Prize ... Physiology or Medicine. The Nobel Committee announced yesterday ... principles for introducing specific gene,modifications in mice by the ...
... Health plans are expecting premium,rate increases in 2008 ... of 8.2%. This is the fourth consecutive decline in ... survey in September of 2007. The survey,contained 76 responses, ... Separately, the survey notes that the East South Central ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... Modes of Operation: , Double Burst : 2 60-ms ... Twitch: 1 s (1 pulse/s) , Tetanus: 50 ... , Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Wave Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Medicine Products: